2361138
Last Update Posted: 2015-02-11
Recruiting has ended
All Genders accepted | 18 Years-45 Years |
48 Estimated Participants | No Expanded Access |
Interventional Study | Accepts healthy volunteers |
The PK/PD Study of Multiple Dose of SHR3824 in Healthy Volunteers
SHR3824 is a novel inhibitor of renal sodium-glucose cotransporter 2, allows an insulin-independent approach to improve type 2 diabetes hyperglycemia. In this multiple-dose study the investigators evaluated the safety, tolerability and PK/PD profiles of SHR3824 in healthy subjects.
Eligibility
Relevant conditions:
Type 2 Diabetes
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the trial if you think are close to fitting criteria.
locations
Contact Information
Overall Contact
No valid contacts available
Data sourced from ClinicalTrials.gov